Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Drug
FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...
MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis
The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...
FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC
US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...
Luye Pharma Launches Erzofri in US Market
China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...
Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...
Zai Lab’s KarXT NDA Accepted by NMPA for Schizophrenia Treatment
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that a New Drug...
Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study
Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...
Wanbangde’s Huperzine A Receives FDA Clearance for HIE Study
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced receiving clearance from the...
FDA Approves Datroway for HR+/HER2- Breast Cancer Treatment
Datroway (datopotamab deruxtecan-dlnk, Dato-Dxd), a Trop-2-directed antibody and topoisomerase inhibitor conjugate co-developed by Japan-based Daiichi...
Allist Pharmaceuticals Gains NMPA Approval for Furmonertinib Clinical Study
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd has announced receiving approval from the National Medical Products...
Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...
Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharm, SHE: 002755) has recently received approval from the...
Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...
Eli Lilly’s Omvoh Approved by FDA for Crohn’s Disease Treatment
US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the...
Boehringer Ingelheim’s Iclepertin Fails to Meet Phase III Study Endpoints
German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study...
Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...
Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M
Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...
Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy
China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...
SciClone and Menarini Submit NDA for Vaborem in China
China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...